Information Provided By: 
Fly News Breaks for February 29, 2016
PTCT
Feb 29, 2016 | 09:03 EDT
Cowen suspended its price target and put its Outperform rating under review for PTC Therapeutics after the company was unable to agree with German reimbursement authorities on price. The company may end up pulling the Ataluren drug from the German market, the firm noted.
News For PTCT From the Last 2 Days
PTCT
Apr 26, 2024 | 21:09 EDT
PTCT
Apr 26, 2024 | 05:57 EDT
PTCT
Apr 25, 2024 | 16:09 EDT
PTCT
Apr 25, 2024 | 16:09 EDT
Reports Q1 revenue $210M, consensus $169.7M. "We are off to a strong start in 2024, with outstanding commercial performance and achievement of all planned clinical and regulatory milestones for the first quarter," said Matthew Klein, M.D., Chief Executive Officer, PTC Therapeutics, Inc. "We remain on track to achieve the many planned 2024 clinical and regulatory milestones, including global regulatory submissions for sepiapterin."
